Illumina, Inc. v. Guardant Health, Inc.

Illumina, Inc. initiated a patent and trade secret litigation against Guardant Health, Inc. in the U.S. District Court for the District of Delaware (Case No. 1:22-cv-00334-GBW-CJB). Both parties are operating biotechnology companies; Illumina is a global leader in DNA sequencing and array-based technologies, providing integrated systems for genetic analysis. Guardant Health is a precision oncology firm specializing in liquid biopsy tests for cancer detection, monitoring, and screening, with products like Guardant360 and Guardant Reveal. The lawsuit centered on allegations that Guardant's co-founders, who were former Illumina employees, misappropriated Illumina's trade secrets related to gene-sequencing technology to develop Guardant's intellectual property, including patents. Illumina sought to be declared the rightful owner of numerous Guardant patents and applications, including U.S. Patent No. 10,793,916. U.S. Patent No. 10,793,916 broadly relates to methods and systems for analyzing nucleic acids, particularly relevant to liquid biopsy and cancer detection technologies.

The case was filed in the U.S. District Court for the District of Delaware, a frequent venue for patent litigation due to the high number of corporations incorporated in Delaware and its experienced judiciary in patent law. District Judge Gregory B. Williams and Magistrate Judge Christopher J. Burke were assigned to the case. This venue became even more prominent for patent suits following the Supreme Court's TC Heartland decision, which restricted venue options. The litigation, filed in March 2022, was ultimately dismissed with prejudice on August 1, 2023, as part of a comprehensive Collaboration and Settlement Agreement between Illumina and Guardant Health.

This dispute was notable given the competitive landscape in the rapidly evolving liquid biopsy and precision oncology market. Guardant Health characterized Illumina's lawsuit as "frivolous and retaliatory," alleging it was an attempt to suppress competition and was prompted by Guardant's concerns regarding Illumina's controversial acquisition of Grail, another blood-based cancer test provider. The settlement not only resolved the intellectual property claims but also included an extension of the companies' commercial relationship, a new long-term purchase and supply commitment, and an agreement to collaborate on sharing specimen samples to advance cancer research. The fact that U.S. Patent No. 10,793,916, which Illumina contested ownership of, was subsequently asserted by Guardant Health in a separate patent infringement suit against Tempus AI, Inc. further highlights the strategic importance and contested nature of the intellectual property involved in this high-stakes industry.

The patent infringement litigation between Illumina, Inc. and Guardant Health, Inc., Case No. 1:22-cv-00334-GBW-CJB, in the U.S. District Court for the District of Delaware, commenced in March 2022 and concluded with a dismissal with prejudice in August 2023 following a settlement.

Here are the key legal developments and outcome:

• Filing & Initial Pleadings:

  • 2022-03-18: Illumina, Inc. filed a lawsuit against Guardant Health, Inc., and its co-CEOs, Helmy Eltoukhy and AmirAli Talasaz, in the U.S. District Court for the District of Delaware. The complaint alleged patent infringement, correction of inventorship, trade secret misappropriation, and breach of contract. Illumina claimed that Guardant's founders stole confidential information while still employed at Illumina to launch Guardant and secure cancer screening patents, including U.S. Patent No. 10,793,916, among others. Guardant Health characterized the lawsuit as "frivolous and retaliatory."
  • 2022-05-25: Guardant Health filed a motion to dismiss Illumina's complaint pursuant to Federal Rules of Civil Procedure 12(b)(1), 12(b)(2), and 12(b)(6).
  • 2022-12-09: Oral argument on Guardant's motion to dismiss was held.
  • 2023-01-31: A Report and Recommendation was issued partially granting and partially denying Guardant's motion to dismiss certain claims, specifically recommending dismissal of claims related to patent applications that had not yet issued. The court noted that Illumina did not intend to press claims on patent applications but rather on patents that may issue from them.

• Pre-trial Motions of Substance:

  • As noted above, Guardant filed a motion to dismiss, which was partially addressed before the case's resolution. No other substantial pre-trial motions, such as motions for transfer, to stay pending IPR (other than the general relevance of IPRs, detailed below), or summary judgment, were fully adjudicated due to the early settlement.

• Claim Construction (Markman) Outcomes:

  • The case did not reach the claim construction stage, given its dismissal prior to such proceedings.

• Discovery Milestones:

  • No strategically significant discovery milestones were reported as the case was dismissed relatively early in the litigation process.

• Trial Events, Verdict, and Post-trial Motions:

  • The case did not proceed to trial.

• Settlement, Dismissal, Judgment:

  • 2023-08-01: Guardant Health, Inc. and Illumina, Inc. announced a Collaboration and Settlement Agreement. Under the terms of this three-year agreement, the parties agreed to extend their commercial relationship, collaborate on sharing specimen samples for cancer research, and enter into a new long-term purchase and supply commitment.
  • 2023-08-01: As part of the settlement, the parties jointly requested to dismiss the pending litigation with prejudice, including all allegations related to the intellectual property at issue. The District Court in Delaware subsequently dismissed the case with prejudice.

• Parallel PTAB IPR/PGR Proceedings:

  • While Guardant Health has been involved in other IPR proceedings challenging different patents (e.g., U.S. Patent No. 10,760,127, owned by the University of Washington), no parallel PTAB IPR or PGR proceedings specifically challenging U.S. Patent No. 10,793,916 in relation to this Illumina v. Guardant litigation were found. The dismissal of the litigation with prejudice, as part of a broader settlement, likely rendered any potential IPRs concerning U.S. Patent No. 10,793,916 moot in the context of this dispute.

I am unable to identify the specific counsel of record representing Illumina, Inc. in Case No. 1:22-cv-00334-GBW-CJB from the public information available through web searches. While the case details and its dismissal with prejudice are confirmed, direct docket entries or news articles explicitly naming Illumina's attorneys in this specific case were not found.

Despite extensive searches through publicly available information, including SEC filings and legal news summaries related to Illumina, Inc. v. Guardant Health, Inc., 1:22-cv-00334-GBW-CJB, the specific counsel of record representing defendant Guardant Health, Inc. in this patent infringement case could not be definitively identified. The available information confirms the case's existence and its dismissal with prejudice, but does not provide a detailed list of the attorneys and their roles for Guardant Health in this particular District of Delaware proceeding.